387 related articles for article (PubMed ID: 35917987)
1. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2.
Moshref Javadi M; Taghdisi Hosseinzadeh M; Soleimani N; Rommasi F
Microb Pathog; 2022 Sep; 170():105687. PubMed ID: 35917987
[TBL] [Abstract][Full Text] [Related]
2. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
3. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
Front Immunol; 2022; 13():974364. PubMed ID: 36159845
[TBL] [Abstract][Full Text] [Related]
4. A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan.
He Y; Yu W; Shen L; Yan W; Xiao L; Qi J; Hu T
Int J Biol Macromol; 2022 Dec; 222(Pt A):661-670. PubMed ID: 36152702
[TBL] [Abstract][Full Text] [Related]
5. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice.
Barbey C; Su J; Billmeier M; Stefan N; Bester R; Carnell G; Temperton N; Heeney J; Protzer U; Breunig M; Wagner R; Peterhoff D
Eur J Pharm Biopharm; 2023 Nov; 192():41-55. PubMed ID: 37774890
[TBL] [Abstract][Full Text] [Related]
9. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.
Lan J; Deng Y; Chen H; Lu G; Wang W; Guo X; Lu Z; Gao GF; Tan W
PLoS One; 2014; 9(11):e112602. PubMed ID: 25405618
[TBL] [Abstract][Full Text] [Related]
10. A SARS-CoV-2 nanoparticle vaccine based on chemical conjugation of loxoribine and SpyCatcher/SpyTag.
Yan W; Yu W; Shen L; Xiao L; Qi J; Hu T
Int J Biol Macromol; 2023 Dec; 253(Pt 5):127159. PubMed ID: 37778577
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of different nanoparticle adjuvants containing recombinant RBD coronavirus antigen in animal model.
Ataei F; Ahmadi A; Fasihi-R M; Kachoei R; Amani J; Najafi A
Biotechnol Appl Biochem; 2024 Apr; 71(2):314-325. PubMed ID: 38037222
[TBL] [Abstract][Full Text] [Related]
12. RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
Phatarphekar A; Vidyadhar Reddy GEC; Gokhale A; Karanam G; Kuchroo P; Shinde K; Masand G; Pagare S; Khadpe N; Pai SS; Vijayan V; Ramnath RL; Pratap Reddy K; Rao P; Harinarayana Rao S; Ramana V
Vaccine; 2022 Jul; 40(32):4522-4530. PubMed ID: 35718590
[TBL] [Abstract][Full Text] [Related]
13. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
Jeong H; Choi YM; Seo H; Kim BJ
Front Immunol; 2021; 12():637654. PubMed ID: 33732258
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
15. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
[TBL] [Abstract][Full Text] [Related]
16. Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
Ramos-Duarte VA; Orlowski A; Jaquenod de Giusti C; Corigliano MG; Legarralde A; Mendoza-Morales LF; Atela A; Sánchez MA; Sander VA; Angel SO; Clemente M
Vaccine; 2024 May; 42(14):3355-3364. PubMed ID: 38631949
[TBL] [Abstract][Full Text] [Related]
17. A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes.
Villarraza J; Fuselli A; Gugliotta A; Garay E; Rodríguez MC; Fontana D; Antuña S; Gastaldi V; Battagliotti JM; Tardivo MB; Alvarez D; Castro E; Cassataro J; Ceaglio N; Prieto C
Appl Microbiol Biotechnol; 2023 Jun; 107(11):3429-3441. PubMed ID: 37093307
[TBL] [Abstract][Full Text] [Related]
18. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
Pitcovski J; Gruzdev N; Abzach A; Katz C; Ben-Adiva R; Brand-Shwartz M; Yadid I; Ratzon-Ashkenazi E; Emquies K; Israeli H; Haviv H; Rapoport I; Bloch I; Shadmon R; Eitan Z; Eliahu D; Hilel T; Laster M; Kremer-Tal S; Byk-Tennenbaum T; Shahar E
Vaccine; 2022 Feb; 40(8):1098-1107. PubMed ID: 35078662
[TBL] [Abstract][Full Text] [Related]
19. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.
Park KS; Bazzill JD; Son S; Nam J; Shin SW; Ochyl LJ; Stuckey JA; Meagher JL; Chang L; Song J; Montefiori DC; LaBranche CC; Smith JL; Xu J; Moon JJ
J Control Release; 2021 Feb; 330():529-539. PubMed ID: 33358977
[TBL] [Abstract][Full Text] [Related]
20. Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models.
Choque-Guevara R; Poma-Acevedo A; Montesinos-Millán R; Rios-Matos D; Gutiérrez-Manchay K; Montalvan-Avalos A; Quiñones-Garcia S; Cauti-Mendoza MG; Agurto-Arteaga A; Ramirez-Ortiz I; Criollo-Orozco M; Huaccachi-Gonzales E; Romero YK; Perez-Martinez N; Isasi-Rivas G; Sernaque-Aguilar Y; Villanueva-Pérez D; Ygnacio F; Vallejos-Sánchez K; Fernández-Sánchez M; Guevara-Sarmiento LA; Fernández-Díaz M; Zimic M;
PLoS One; 2022; 17(8):e0269823. PubMed ID: 35998134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
